Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

NCT00387751 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

NIH

Sponsor class

Conditions

Recurrent Melanoma
Stage III Skin Melanoma
Stage IV Skin Melanoma

Interventions

BIOLOGICAL: Bevacizumab
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Sorafenib Tosylate

Sponsor

National Cancer Institute (NCI)